Acute severe colitis: Infliximab and/or cyclosporine?

Current Drug Targets

Volumn 12, Issue 10, 2011, Pages 1448-1453

  Fabro, Mauro ^a   Szabo, Hajnalka ^c   Terrosu, Giovanni ^b   Avellini, Claudio ^a   Tabuso, Maria ^a   Fiorino, Gionata ^c   Sorrentino, Dario ^a,d  

^a Department of Clinical and Experimental Pathology ^*  (Italy)

^b Digestive Surgery   (Italy)

^c UNIVERSITY OF UDINE   (Italy)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Colectomy; Corticosteroids; Cyclosporine; Infliximab; Severe colitis

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; GLUCOCORTICOID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHYLPREDNISOLONE; PLACEBO; STEROID;

ANKYLOSING HYPEROSTOSIS; ARTICLE; ASPERGILLUS FUMIGATUS; COLITIS; CROHN DISEASE; DISEASE SEVERITY; DRUG MEGADOSE; GINGIVA HYPERPLASIA; GRAND MAL SEIZURE; HAIR LOSS; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; LOW DRUG DOSE; PARESTHESIA; PNEUMOCYSTIS CARINII; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SIDE EFFECT; TREMOR; ULCERATIVE COLITIS;

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80051699715     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011796818234     Document Type: Article

References (32)

1. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 1955; 2: 1041-1048.
2. Stange EF, Travis SPL, Vermeire S. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definition and diagnosis. J Crohns Colitis 2008; 2: 1-23.
3. Carter MJ, Lobo AJ, Travis SPL. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53(Suppl 5): 1-16.
4. Jakobovits SL, Travis SPL. Management of acute severe colitis. Br Med Bull 2006; 75-76: 131-144.
5. Hong SK, Maltz BE, Coburn LA, et al. Increased serum levels of Larginine in ulcerative colitis and correlation with disease severity. Inflamm Bowel Dis 2010; 16(1): 105-111.
6. Turner D, Walsh C, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007; 5: 103-110.
7. Travis SPL, Stange EF, Lémann M. European evidence-based Consensus on themanagement of ulcerative colitis: current management. J Crohns Colitis 2008; 2: 24-62.
8. Järnerot G, Rolny P, Sandberg-Gertzén H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985; 89: 1005-1013.
9. Lindgren SC, Flood LM, Kilander AF. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998; 10: 831-835.
10. Italia JL, Bhardway V, Kumar MNV. Disease, destination, dose and delivery aspects of ciclosporin: the state of the art. Drugs Discov Today 2006; 11: 846-854.
11. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-1845.
12. D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120: 1323-1329.
13. van Assche G, D'Haens G, Noman M, et al. Randomized, doubleblind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125: 1025-1031.
14. Arts J, D'Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004; 10: 73-78.
15. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94: 1587-1592.
16. Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006; 4: 760-765.
17. Bamba S, Tsujikawa T, Inatomi O, et al. Factors affecting the efficacy of cyclosporin A therapy for refractory ulcerative colitis. J Gastroenterol Hepatol 2010; 25: 494-498.
18. Atzeni F, Doria A, Carrabba M. Potential target of infliximab in autoimmune and inflammatory diseases. Autoimm Rev 2007; 6: 529-536.
19. Rutgeerts P, Sandborn WJ, Feagan BG. Infliximab for induction and maintenance therapy for ulcerative colitis. NEJM 2005; 353: 2462-2476.
20. Feagan BG, Reinisch W, Rutgeerts P, et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007; 102: 794-802. Erratum in: Am J Gastroenterol 2007; 102: 1338.
21. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009; 137: 1250-1260.
22. Kohn A, Prantera C, Pera A, Cosintino R, Sostegni R, Daperno M. Anti-tumor necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. Dig Liv Dis 2002; 34: 626-630.
23. Lees CW, Heys D, Ho GT, et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Parmacol Ther 2007; 26: 411-419.
24. Aratari A, Papi C, Clemente V, et al. Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liv Dis 2008; 40: 821-826.
25. Chey W. Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis 2001; 1: s30-s33.
26. Kohn A, Daperno M, Armuzzi A, et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow- up. Aliment Pharmacol Ther 2007; 26: 747-756.
27. Jakobovits SL, Jewell DP, Travis SPL. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2002 to 2006. Aliment Pharmacol Ther 2007; 25: 1055-1060.
28. Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-1811.
29. Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology 2010; 138: 2282-2291.
30. Hanauer SB. Infliximab or cyclosporine for severe ulcerative colitis. Gastroenterology 2005; 129: 1358-1359.
31. Wilhelm SM, McKenney KA, Rivait KN. A review of infliximab use in ulcerative colitis. Clin Ther 2008; 30: 223-230.
32. Laharie D, Bourreille A, Branche J, et al. Cyclosporine vs. Infliximab in severe acute Ulcerative Colitis refractory to intravenous stroids: a randomised trail. Program and abstracts of digestive diseases week 2011; May 7-10, 2011, Chicago, Illinois, Abstract 619.